## Gene Summary
CYSLTR2, or Cysteinyl Leukotriene Receptor 2, is a gene encoding for a protein that belongs to the cysteinyl leukotriene receptor family. It is involved in mediating the effects of cysteinyl leukotrienes (CysLTs), which are lipid molecules implicated in inflammatory processes, particularly in the respiratory tract. CYSLTR2 is expressed predominantly in inflammatory cells but also in various tissues including heart and central nervous system tissues. The receptor encoded by CYSLTR2 binds leukotrienes, particularly leukotriene C4, D4, and E4, which play a significant role in bronchoconstriction, inflammation, and allergic responses.

## Gene Drugs, Diseases, Phenotypes, and Pathways
CYSLTR2 is pharmacologically significant in relation to asthma, allergic rhinitis, and cardiovascular diseases like atherosclerosis. The interaction of CYSLTR2 with leukotrienes is crucial in the pathophysiology of asthma, contributing to airway edema, smooth muscle contraction, and altered cellular activity associated with inflammation. Mutations in CYSLTR2 have been sporadically linked with uveal melanoma, suggesting a possible role in tumorigenesis. In terms of pathways, CYSLTR2 is vital in the leukotriene signaling pathway which plays a pivotal role in the inflammatory response, particularly in pulmonary and cardiovascular systems.

## Pharmacogenetics
In the context of pharmacogenetics, CYSLTR2 has implications primarily in the treatment of asthma. Montelukast and zafirlukast, which are leukotriene receptor antagonists, specifically target receptors like CYSLTR2 to manage and treat asthma symptoms and inflammation by blocking the binding of leukotrienes to these receptors. The efficacy and response to these treatments can vary significantly between individuals, potentially influenced by genetic variations in the CYSLTR2 gene. Research into these variations might reveal important genetic markers that predict patient responses to these drugs, therefore optimizing the management strategies for asthma and potentially other inflammatory conditions mediated by cysteinyl leukotrienes.